BladderCell is designed to utilize bioelectric signaling and biologics to treat bladder disorders such as an over-active bladder.
Playa Vista, CA, Salt Lake City, Utah and Pittsburgh, PA (PRReleaseJet) – Today the team at Leonhardt’s Launchpads announced the launch of a new startup BladderCell that will focus on the development of bioelectric treatments for bladder disorders.
The original patent pending BladderCell device design has these primary components to its candidate therapy.
- Bioelectric signal sequences for recruiting (via SDF1 and PDGF), proliferating and differentiating stem cells into bladder muscle.
- Bioelectric signal sequences communicating with the nervous system for neuromodulation control of bladder.
- Bioelectric signals for controlling release of follistatin, tropoelastin, EGF, HGF and other proteins for regenerating bladder function.
- Micro infusion pump for repeat deliveries of BC-15 bladder regeneration composition.
- Fifteen component BC-15 bladder regeneration composition comprised of muscle stem cells, growth factors, exosomes, micro RNA gel, PRF, amniotic fluid, selected alkaloids, nutrient hydrogel, follistatin, SDF1, oxygenated nanoparticles and bladder matrix.
“The BladderCell therapy is the first candidate therapy known to combine the benefits of bioelectrics and biologics to attempt to regenerate failing or overactive bladders,” states Dr. Leslie Miller, Chief Medical Officer.
“Bladder incontinence is increasingly being recognized as a major women’s health issue. It is twice as common in women as in men. Our team is determined to bring a better solution to the millions suffering of this disorder.” — Laurelle Johnson, BladderCell founding partner
URINARY INCONTINENCE – RECOGNITION AS A MAJOR WOMEN’S HEALTH ISSUE OF CONCERN
- Of the 25 million adult Americans suffering from urinary incontinence, 75–80% are women.
- Urinary incontinence affects 200 million people worldwide.
- One in four women over 18 experience urine leakage.
- Women wait 6.5 years on average before diagnosis.
- Stress urinary incontinence affects ~15 million women in the U.S.
- About 17% of women and 16% of men have OAB.
- Urinary incontinence is twice as common in women.
- Pregnancy, childbirth, and menopause increase risk.
- 24% of women aged 18–44 experience incontinence.
- 23% of women over 60 deal with incontinence.
Sources
- National Association for Incontinence – Facts and Statistics
- WomensHealth.gov – Urinary incontinence fact sheet
- American Medical Systems – Urinary incontinence
About BladderCell
BladderCell is a startup incubating in Leonhardt’s Launchpads innovation accelerators in Playa Vista, CA; Salt Lake City, Utah; and Pittsburgh, PA.
About Leonhardt’s Launchpads
Founded by Leonhardt Ventures in 2008, focusing on regenerative medtech startups across multiple U.S. and international locations. The platform develops bioelectric stimulation technologies combined with biologics for organ regeneration.
About Leonhardt Ventures
Founded in 1982, led development of major organ regeneration and vascular repair technologies, treating over 500,000 patients worldwide.
Cautionary Statement
Early-stage technologies are unproven for safety and efficacy. Investments are high risk and intended only for sophisticated investors.
Company Locations
Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc.
12655 W Jefferson Blvd, Los Angeles, CA 90066
Leonhardt’s Launchpads Utah, Inc.
370 S, 300 E, Salt Lake City, UT 84111
Research Lab: 2500 S State St. #224, Salt Lake City, UT 84115
Leonhardt’s Launchpads Pittsburgh, Inc.
2730 Sidney Street, Suite 300
Pittsburgh, PA 15203